Clinical Trial

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2028-06-28 -> 2028-07-28 2026-07-28
minor Completion pushed: 2028-06-28 -> 2028-07-28 2026-07-28
notable Trial sites expanded: 10 -> 14 locations 2026-06-05
notable Trial sites expanded: 2 -> 6 locations 2026-04-21
Trial Details
NCT Number NCT07403721
Lead Sponsor Amgen
Conditions Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Enrollment 464 participants
Start Date 2026-04-08
Primary Completion 2028-07-28 (estimated)
Study Completion 2028-07-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-07